COLUMBUS, Ohio – Adding low doses of the targeted agent sorafenib to the chemotherapy and radiation now often used to treat head and neck cancer might significantly improve patient care and quality of life, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The findings suggest that adding sorafenib would maintain treatment efficacy while permitting the use of lower doses of chemotherapy and radiation and decreasing the treatment’s harsh side effects. The triple combination was well-tolerated in an animal model.
About 49,200 new cases of head and neck cancer
are expected in the U.S. this year, and 11,500 people are expected to die of the disease. Treatment is often unsuccessful because the tumors become resistant to both chemotherapy and radiation therapy.
“This pre-clinical study suggests that using low-dose sorafenib
along with chemotherapy and radiation could have significantly milder side effects while maintaining effectiveness,” says researcher and principal investigator Dr. Pawan Kumar, assistant professor of otolaryngology and head and neck surgery at the OSUCCC – James.
“Our findings provide a scientific rationale to evaluate this combination strategy through a clinical trial,” Kumar added.
of the laboratory and animal study are published online in the journal Molecular Cancer Therapeutics
, and they include the following:
- Sorafenib sensitized tumor cells to chemotherapy and radiation treatment by down-regulating DNA repair proteins (ERCC-1 and XRCC-1), and it decreased tumor angiogenesis by inhibiting VEGF-mediated signaling.
- The combination treatment was well tolerated in a mouse model and significantly inhibited tumor growth and tumor angiogenesis; low-dose sorafenib alone was an effective maintenance regimen.
- The combination treatment significantly inhibited tumor-cell migration, invasion and the formation of new tumor blood vessels in laboratory studies.
“Taken together, our results suggest a potentially novel strategy in which sorafenib combined with low doses of chemotherapy, radiation therapy, or both is as effective in the treatment of head and neck cancer as much higher doses used in existing treatment approaches,” says study co-author Dr. Theodoros N. Teknos, professor of otolaryngology, director of head and neck oncologic surgery, and the David E. and Carole H. Schuller Chair in Head and Neck Oncologic Surgery. “As a result, it may be possible to design new treatment regimens that limit side effects of therapy without decreasing cure rates.”
Funding from the National Cancer Institute and Joan’s Fund supported this research.
Other Ohio State researchers involved in this study were Arti Yadav and Bhavna Kumar.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (http://cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top cancer hospitals in the nation, The James is the 205-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven programs in the country funded by the NCI to conduct both Phase I and Phase II clinical trials.###
Darrell E. Ward
Medical Center Communications